Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

AstraZeneca's Iressa May Pave Way For EGFR Inhibitors In Adjuvant Lung Cancer

Executive Summary

Study done in China may prompt a change the standard of care in the US to include earlier testing for EGFR mutations after surgery, but is unlikely to change treatment protocols until overall survival data are available.

You may also be interested in...



AstraZeneca Upbeat On China Prospects For New Products

China continues to be the brightest star in AstraZeneca's emerging markets firmament amid some "softness" in other countries, and the UK group sees attractive prospects in the country for some of its innovative branded products.

AstraZeneca’s Iressa, Now Resurrected, Faces Daunting U.S. EGFR Market

AstraZeneca sees an edge on safety for Iressa, which was traditionally perceived as having attractive tolerability relative to other EGFR inhibitors, but firm still has a tough road competing against the omnipresent Tarceva.

AstraZeneca's Iressa Use Narrowed: No New Commercial Patients

Revised labeling for the oncologic restricts use to patients who have already received the drug and benefited from it, as well as certain clinical trial participants. Beginning Sept. 15, Iressa patients will have to refill prescriptions through a single mail order pharmacy.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC098764

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel